Endra Life SciencesNDRA
13F holders, Q4 2025 (December 31)7holders +2
4new positions
2sold out
$4.53avg. 13F price*
At the end of Q4 2025, 7 institutions reported holding Endra Life Sciences Inc. (NDRA) in their 13F filings, up 2 from Q3 2025. 4 opened new positions and 2 sold out. The largest holders were Altium Capital Management LLC ($235K), Vanguard Group Inc. ($59K) and Morgan Stanley ($31K).
- Company
- Endra Life Sciences Inc.
- CUSIP
- 29273B500
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2025 → Q4 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 4 | $325K |
| Exits | 2 | $70K |
All 13F filers, Q3 2025 → Q4 2025: 71,788 shares bought and 13,049 shares sold, net +58,739 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 7 holders
| Altium Capital Management LLC | 0.93% | New | 51,900 | $235K |
| Vanguard Group Inc. | 0.00% | New | 12,937 | $59K |
| Morgan Stanley | 0.00% | New | 6,946 | $31K |
| Northwestern Mutual Wealth Management Co. | 0.00% | Reduce -45.7% | 19 | $86 |
| UBS Group AG | 0.00% | Reduce -88.7% | 12 | $54 |
| Bank of America Corp. | 0.00% | Add +66.7% | 10 | $45 |
| Citigroup Inc. | 0.00% | New | 1 | $5 |
"% of holder's portfolio" is NDRA's weight in each manager's 13F, not the share of Endra Life Sciences Inc. the manager owns.